

12-11-2007

本公司新闻：

标题：SFDA 批准福建三爱为全国首三家鱼腥草注射液恢复生产销售

本集团欣然宣布，中国国家食品药品监督管理局(“SFDA”)于2007年11月7日批准恢复本公司全资子公司福建三爱药业有限公司(“福建三爱”)就有关鱼腥草注射液(2ml)生产销售之申请。

该产品于全国原有生产商约有三十多家，目前全国只有三家企业获准生产，福建三爱为其中之一。本集团管理层相信该产品之相关生产优势，将于不久将来为本集团之销售及毛利带来贡献。

SFDA已经对本集团的生产情况和条件进行现场核查，审查结果符合恢复鱼腥草注射液肌内注射使用的相关要求，反映SFDA对福建三爱实力及其生产相关产品能力之肯定。

Company News

Fujian Sanai obtained SFDA approval to resume production and sales of Yuxingcao Injectable

We are pleased to announce that the State Food and Drug Administration (SFDA) of China has approved Fujian Sanai Pharmaceutical Co. Ltd. (“Fujian Sanai”), our wholly owned subsidiary, to resume its production and sales of Yuxingcao Injectable (2ml) on 7 November 2007.

Fujian Sanai is one of the three manufacturers allowed to produce this product. Originally there were over 30 manufactures producing this product. The management of the Company believes that this product, which enjoys the relevant production advantage, will contribute to our turnover and gross profit in the near future.

SFDA has examined Fujian Sanai’s production facilities. The result shows that our Yuxingcao Injectable conforms to SFDA’s requirement, which further proves SFDA’s recognition on Fujian Sanai and its production capability.